| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 139.04% | B. Riley Securities | → $6 | Reiterates | Buy → Buy |
| 07/12/2023 | 139.04% | B. Riley Securities | $3 → $6 | Maintains | Buy |
| 05/23/2023 | 19.52% | B. Riley Securities | $6 → $3 | Maintains | Buy |
| 03/30/2023 | 139.04% | B. Riley Securities | → $6 | Reiterates | → Buy |
| 02/25/2022 | 258.57% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 12/16/2021 | 497.61% | Roth Capital | → $15 | Initiates Coverage On | → Buy |
| 12/07/2021 | 457.77% | B. Riley Securities | → $14 | Initiates Coverage On | → Buy |
| 02/03/2020 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 01/23/2020 | 647.01% | HC Wainwright & Co. | → $18.75 | Downgrades | Buy → Neutral |
| 06/06/2019 | 457.77% | Mizuho | $17 → $14 | Upgrades | Neutral → Buy |
| 06/06/2019 | 457.77% | Mizuho | $17 → $14 | Upgrades | Neutral → Buy |
| 02/14/2019 | 417.93% | HC Wainwright & Co. | → $13 | Initiates Coverage On | → Buy |
| 01/17/2019 | — | Raymond James | Upgrades | Underperform → Market Perform |
What is the target price for Journey Medical (DERM)?
The latest price target for Journey Medical (NASDAQ: DERM) was reported by B. Riley Securities on September 7, 2023. The analyst firm set a price target for $6.00 expecting DERM to rise to within 12 months (a possible 139.04% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Journey Medical (DERM)?
The latest analyst rating for Journey Medical (NASDAQ: DERM) was provided by B. Riley Securities, and Journey Medical reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Journey Medical (DERM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Journey Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Journey Medical was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Journey Medical (DERM) correct?
While ratings are subjective and will change, the latest Journey Medical (DERM) rating was a reiterated with a price target of $0.00 to $6.00. The current price Journey Medical (DERM) is trading at is $2.51, which is within the analyst's predicted range.